Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 16, 2023
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
D C Gilbert, M Nankivell, H Rush, et al.
The Lancet. Oncology
|
April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials
Mahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 6, 2026
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer
C T A Parker, H-C Huang, E Grist, et al.
Plos Medicine
|
June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
Chris C Parker, Nicholas D James, Christopher D Brawley, et al.
The Lancet. Digital Health
|
June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol
Charles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.
Cell
|
August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
Emily Grist, Peter Dutey-Magni, Marina A Parry, et al.
Lancet (London, England)
|
December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Gerhardt Attard, Laura Murphy, Noel W Clarke, et al.
The New England Journal of Medicine
|
June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)
|
October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C Parker, Nicholas D James, Christopher D Brawley, et al.
The New England Journal of Medicine
|
March 25, 2026
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer
Ruth E Langley, Duncan C Gilbert, Stephen Mangar, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 16, 2023
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
D C Gilbert, M Nankivell, H Rush, et al.
The Lancet. Oncology
|
April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials
Mahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 6, 2026
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer
C T A Parker, H-C Huang, E Grist, et al.
Plos Medicine
|
June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
Chris C Parker, Nicholas D James, Christopher D Brawley, et al.
The Lancet. Digital Health
|
June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol
Charles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.
Cell
|
August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
Emily Grist, Peter Dutey-Magni, Marina A Parry, et al.
Lancet (London, England)
|
December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Gerhardt Attard, Laura Murphy, Noel W Clarke, et al.
The New England Journal of Medicine
|
June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)
|
October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C Parker, Nicholas D James, Christopher D Brawley, et al.
The New England Journal of Medicine
|
March 25, 2026
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer
Ruth E Langley, Duncan C Gilbert, Stephen Mangar, et al.
Page
of 6